These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36091057)

  • 1. C5a elevation in convalescents from severe COVID-19 is not associated with early complement activation markers C3bBbP or C4d.
    Kowalska D; Kuźniewska A; Senent Y; Tavira B; Inogés S; López-Díaz de Cerio A; Pio R; Okrój M; Yuste JR
    Front Immunol; 2022; 13():946522. PubMed ID: 36091057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escalated complement activation during hospitalization is associated with higher risk of 60-day mortality in SARS-CoV-2-infected patients.
    Barratt-Due A; Pettersen K; Børresdatter-Dahl T; Holter JC; Grønli RH; Dyrhol-Riise AM; Lerum TV; Holten AR; Tonby K; Trøseid M; Skjønsberg OH; Granerud BK; Heggelund L; Kildal AB; Schjalm C; Aaløkken TM; Aukrust P; Ueland T; Mollnes TE; Halvorsen B;
    J Intern Med; 2024 Jul; 296(1):80-92. PubMed ID: 38539241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of High Levels of Serum Complement C5a in Severe COVID-19 Cases After Hospital Discharge.
    Senent Y; Inogés S; López-Díaz de Cerio A; Blanco A; Campo A; Carmona-Torre F; Sunsundegui P; González-Martín A; Ajona D; Okrój M; Prósper F; Pio R; Yuste JR; Tavira B
    Front Immunol; 2021; 12():767376. PubMed ID: 34868021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythrocytes identify complement activation in patients with COVID-19.
    Lam LKM; Reilly JP; Rux AH; Murphy SJ; Kuri-Cervantes L; Weisman AR; Ittner CAG; Pampena MB; Betts MR; Wherry EJ; Song WC; Lambris JD; Meyer NJ; Cines DB; Mangalmurti NS
    Am J Physiol Lung Cell Mol Physiol; 2021 Aug; 321(2):L485-L489. PubMed ID: 34231390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement C5a and Clinical Markers as Predictors of COVID-19 Disease Severity and Mortality in a Multi-Ethnic Population.
    Cyprian FS; Suleman M; Abdelhafez I; Doudin A; Masud Danjuma M; Mir FA; Parray A; Yousaf Z; Siddiqui MYA; Abdelmajid A; Mulhim M; Al-Shokri S; Abukhattab M; Shaheen R; Elkord E; Al-Khal AL; Elzouki AN; Girardi G
    Front Immunol; 2021; 12():707159. PubMed ID: 34966381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lectin Pathway Mediates Complement Activation by SARS-CoV-2 Proteins.
    Ali YM; Ferrari M; Lynch NJ; Yaseen S; Dudler T; Gragerov S; Demopulos G; Heeney JL; Schwaeble WJ
    Front Immunol; 2021; 12():714511. PubMed ID: 34290717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional Activity of the Complement System in Hospitalized COVID-19 Patients: A Prospective Cohort Study.
    Charitos P; Heijnen IAFM; Egli A; Bassetti S; Trendelenburg M; Osthoff M
    Front Immunol; 2021; 12():765330. PubMed ID: 34777382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Persistently elevated complement alternative pathway biomarkers in COVID-19 correlate with hypoxemia and predict in-hospital mortality.
    Leatherdale A; Stukas S; Lei V; West HE; Campbell CJ; Hoiland RL; Cooper J; Wellington CL; Sekhon MS; Pryzdial ELG; Conway EM
    Med Microbiol Immunol; 2022 Feb; 211(1):37-48. PubMed ID: 35034207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement activation products in the circulation and urine of primary membranous nephropathy.
    Zhang MF; Huang J; Zhang YM; Qu Z; Wang X; Wang F; Meng LQ; Cheng XY; Cui Z; Liu G; Zhao MH
    BMC Nephrol; 2019 Aug; 20(1):313. PubMed ID: 31399080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromosome 3 cluster rs11385942 variant links complement activation with severe COVID-19.
    Valenti L; Griffini S; Lamorte G; Grovetti E; Uceda Renteria SC; Malvestiti F; Scudeller L; Bandera A; Peyvandi F; Prati D; Meroni P; Cugno M
    J Autoimmun; 2021 Feb; 117():102595. PubMed ID: 33453462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring Circulating Complement Activation Products in Myeloperoxidase- and Proteinase 3-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.
    Wu EY; McInnis EA; Boyer-Suavet S; Mendoza CE; Aybar LT; Kennedy KB; Poulton CJ; Henderson CD; Hu Y; Hogan SL; Hu P; Xiao H; Nachman PH; Jennette JC; Falk RJ; Bunch DO
    Arthritis Rheumatol; 2019 Nov; 71(11):1894-1903. PubMed ID: 31215772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-C5a antibody vilobelimab treatment and the effect on biomarkers of inflammation and coagulation in patients with severe COVID-19: a substudy of the  phase 2 PANAMO trial.
    Lim EHT; Vlaar APJ; Bos LDJ; van Vught LA; Boer AMT; Dujardin RWG; Habel M; Xu Z; Brouwer MC; van de Beek D; de Bruin S;
    Respir Res; 2022 Dec; 23(1):375. PubMed ID: 36566174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complement activation and endothelial perturbation parallel COVID-19 severity and activity.
    Cugno M; Meroni PL; Gualtierotti R; Griffini S; Grovetti E; Torri A; Lonati P; Grossi C; Borghi MO; Novembrino C; Boscolo M; Uceda Renteria SC; Valenti L; Lamorte G; Manunta M; Prati D; Pesenti A; Blasi F; Costantino G; Gori A; Bandera A; Tedesco F; Peyvandi F
    J Autoimmun; 2021 Jan; 116():102560. PubMed ID: 33139116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement activation predicts negative outcomes in COVID-19: The experience from Northen Italian patients.
    Meroni PL; Croci S; Lonati PA; Pregnolato F; Spaggiari L; Besutti G; Bonacini M; Ferrigno I; Rossi A; Hetland G; Hollan I; Cugno M; Tedesco F; Borghi MO; Salvarani C
    Autoimmun Rev; 2023 Jan; 22(1):103232. PubMed ID: 36414219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer.
    Ajona D; Razquin C; Pastor MD; Pajares MJ; Garcia J; Cardenal F; Fleischhacker M; Lozano MD; Zulueta JJ; Schmidt B; Nadal E; Paz-Ares L; Montuenga LM; Pio R
    PLoS One; 2015; 10(3):e0119878. PubMed ID: 25799154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The synthesis of a water soluble complement activating polyacrylic acid-IgG polymer.
    Schmer G; Henderson RA; Müller W
    J Biomater Sci Polym Ed; 1994; 6(1):67-78. PubMed ID: 7947474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Involvement of the complement cascade in severe forms of COVID-19].
    Chouaki Benmansour N; Carvelli J; Vivier É
    Med Sci (Paris); 2021 Apr; 37(4):333-341. PubMed ID: 33835019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement activation pathways in murine immune complex-induced arthritis and in C3a and C5a generation in vitro.
    Banda NK; Levitt B; Wood AK; Takahashi K; Stahl GL; Holers VM; Arend WP
    Clin Exp Immunol; 2010 Jan; 159(1):100-8. PubMed ID: 19843088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A disturbed balance between blood complement protective factors (FH, ApoE) and common pathway effectors (C5a, TCC) in acute COVID-19 and during convalesce.
    Laudanski K; Okeke T; Siddiq K; Hajj J; Restrepo M; Gullipalli D; Song WC
    Sci Rep; 2022 Aug; 12(1):13658. PubMed ID: 35953544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement activation in platelet concentrates is surface-dependent and modulated by the platelets.
    Gyongyossy-Issa MI; McLeod E; Devine DV
    J Lab Clin Med; 1994 Jun; 123(6):859-68. PubMed ID: 8201264
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.